MacroGenics (MGNX) Earning Somewhat Favorable Press Coverage, Report Finds
Headlines about MacroGenics (NASDAQ:MGNX) have trended somewhat positive on Friday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MacroGenics earned a daily sentiment score of 0.03 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.7367608792151 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern’s rankings:
- MacroGenics Announces Closing of MGA012 Global Collaboration and License Agreement with Incyte (finance.yahoo.com)
- MacroGenics, Inc. (MGNX) Expected to Announce Quarterly Sales of $152.60 Million (americanbankingnews.com)
- MacroGenics (MGNX) Upgraded by ValuEngine to “Sell” (americanbankingnews.com)
- Zacks: Analysts Expect MacroGenics, Inc. (MGNX) to Post $2.58 EPS (americanbankingnews.com)
MGNX has been the subject of a number of research analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and issued a $34.00 target price on shares of MacroGenics in a research note on Tuesday, September 12th. Cowen reaffirmed a “buy” rating on shares of MacroGenics in a research note on Wednesday, October 25th. Zacks Investment Research downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. SunTrust Banks reaffirmed a “buy” rating and issued a $26.00 target price on shares of MacroGenics in a research note on Friday, September 1st. Finally, ValuEngine upgraded shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $30.10.
MacroGenics (NASDAQ:MGNX) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). The firm had revenue of $1.70 million for the quarter, compared to analyst estimates of $5.50 million. MacroGenics had a negative net margin of 1,526.55% and a negative return on equity of 69.31%. The firm’s revenue for the quarter was down 48.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.97) EPS. analysts anticipate that MacroGenics will post -0.7 earnings per share for the current year.
In related news, SVP Jon Marc Wigginton sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the senior vice president now owns 35,000 shares in the company, valued at $700,000. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 8.30% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: “MacroGenics (MGNX) Earning Somewhat Favorable Press Coverage, Report Finds” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/08/macrogenics-mgnx-earning-somewhat-favorable-press-coverage-report-finds.html.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Stock Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related stocks with our FREE daily email newsletter.